L-Bcl-2 antisense oligonucleotide

Phase 1Peptide

L-Bcl-2 antisense oligonucleotide is one of 6 small molecule programs targeting Lymphoid Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoid MalignanciesActive, not recruiting

Lymphoid MalignanciesPhase 1

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Lymphoid Malignancies

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 2

6 2

Cytoxan

BBaxter Healthcare Corporation

Phase 2

7 3

Tazverik

EEpizyme, Inc.

Phase 1

1 4

Folotyn

AAcrotech Biopharma Inc.

Preclinical

1 5

AVM0703

AAVM Biotechnology Inc

Phase 2

1 6

L-Bcl-2 antisense oligonucleotide

BBio-Path Holdings, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoid Malignancies1 trial

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Active, not recruiting·BBio-Path Holdings, Inc.·Phase 1·NCT04072458·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for L-Bcl-2 antisense oligonucleotide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L-Bcl-2 antisense oligonucleotide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L-Bcl-2 antisense oligonucleotide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bio-Path Holdings, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 1[1]
Company: BBio-Path Holdings, Inc.

L-Bcl-2 antisense oligonucleotide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoid Malignancies1 trial

References

Drug Info

Quick Facts

Related News